UPDATE 1-Eli Lilly considers sale of off-patent drug assets in China - Bloomberg

Eli Lilly and Co is considering the sale of an off-patent drugs portfolio in China, Bloomberg reported on Friday, citing sources.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.